Glaukos (NYSE:GKOS) Posts Earnings Results, Beats Expectations By $0.57 EPS

Posted by Geri Gentry on Oct 29th, 2026

Glaukos (NYSE:GKOS – Get Free Report) issued its earnings results on Wednesday. The medical instruments supplier reported $0.47 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.57, FiscalAI reports. The firm had revenue of $211.03 million during the quarter, compared to analysts’ expectations of $168.04 million. Glaukos had a negative net margin of 30.68% and a negative return on equity of 6.37%. The firm’s revenue was up 58.0% compared to the same quarter last year. During the same quarter last year, the company posted ($0.16) earnings per share.

Here are the key takeaways from Glaukos’ conference call:

Record third-quarter net sales reached $211 million, up 58% year over year. Glaukos raised 2026 revenue guidance to $775 million–$785 million and issued preliminary 2027 guidance of approximately $1 billion.
Epioxa generated approximately $53 million in third-quarter sales during its early launch, supported by access pathways covering about 90% of U.S. commercial lives and more than 80% of Medicaid lives. The company is expanding treatment sites, referral networks, disease awareness efforts, and patient-support infrastructure.
iDose TR sales reached approximately $76 million, with the U.S. glaucoma franchise growing 47% year over year. A phase IV study showed an 11.1 mmHg reduction in intraocular pressure and a statistically significant 3.6 mmHg incremental benefit when iDose was added to cataract surgery.
Potential Medicare local coverage determinations for iDose remain an important uncertainty. Management said its $1 billion 2027 outlook considers restrictive LCD scenarios, but the timing and final terms remain unknown and could affect iDose utilization.
Profitability and cash generation improved as the business scaled, with non-GAAP gross margin near 88%, more than $50 million in quarterly cash generation, and $28.5 million in non-GAAP net income. Management expects gross-margin durability as Epioxa and iDose become a larger share of revenue, while continuing substantial investment in its ophthalmology pipeline.

Glaukos Price Performance

NYSE GKOS traded up $54.72 during trading hours on Thursday, reaching $236.15. The company’s stock had a trading volume of 3,102,547 shares, compared to its average volume of 889,948. The firm has a market capitalization of $13.93 billion, a price-to-earnings ratio of -72.64 and a beta of 0.69. Glaukos has a 1-year low of $80.90 and a 1-year high of $241.47. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.04 and a quick ratio of 4.46. The company’s 50-day moving average is $171.24 and its two-hundred day moving average is $139.87.

Insiders Place Their Bets

In other news, Director Gilbert H. Kliman sold 2,500 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $190.00, for a total transaction of $475,000.00. Following the completion of the transaction, the director directly owned 37,406 shares of the company’s stock, valued at $7,107,140. This represents a 6.26% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, COO Joseph Gilliam sold 60,000 shares of the stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $179.74, for a total transaction of $10,784,400.00. Following the transaction, the chief operating officer directly owned 72,588 shares in the company, valued at approximately $13,046,967.12. The trade was a 45.25% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 83,025 shares of company stock valued at $14,950,006 in the last three months. 5.90% of the stock is currently owned by company insiders.

Key Glaukos News

Here are the key news stories impacting Glaukos this week:

Positive Sentiment: Record quarterly results: Third-quarter revenue rose 58% year over year to approximately $211 million, well above the roughly $168 million analyst consensus. The company reported adjusted earnings of $0.47 per share, compared with expectations for a loss, while GAAP net income was approximately $2 million. Glaukos Q3 Earnings and Revenues Surpass Estimates
Positive Sentiment: Higher 2026 guidance: Management raised full-year 2026 sales guidance to $775 million-$785 million from $680 million-$700 million, signaling stronger-than-expected demand and execution. Glaukos Swings to Profit in Q3 and Lifts Guidance
Positive Sentiment: Large 2027 sales opportunity: Glaukos provided preliminary 2027 sales guidance of approximately $1 billion. The target suggests management expects continued momentum from products including iDose TR and Epioxa. Glaukos Provides 2027 Sales Guidance
Positive Sentiment: Analyst support: Needham raised its price target to $251 from $201 and maintained a buy rating. BTIG increased its target to $234 from $205, while Stifel raised its target to $225 from $190. Wells Fargo lifted its target to $226 and assigned an overweight rating. These revisions reflect improved earnings and growth expectations.
Neutral Sentiment: Valuation remains demanding: Although results exceeded expectations, several revised price targets remain near or below the recent trading level, suggesting analysts see limited near-term upside after the sharp rally.
Negative Sentiment: Insider selling: Reported insider activity over the past six months showed 32 open-market sales and no purchases. This may temper enthusiasm, although the sales do not necessarily indicate a change in the company’s operating outlook.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on GKOS shares. Mizuho set a $225.00 price target on Glaukos in a research report on Thursday. Stifel Nicolaus boosted their price objective on Glaukos from $190.00 to $225.00 and gave the company a “buy” rating in a report on Thursday. UBS Group began coverage on Glaukos in a research note on Tuesday, July 28th. They issued a “neutral” rating and a $150.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and set a $248.00 target price on shares of Glaukos in a report on Thursday. Finally, Needham & Company LLC raised their target price on Glaukos from $201.00 to $251.00 and gave the stock a “buy” rating in a report on Thursday. Thirteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $205.36.

Check Out Our Latest Report on GKOS

Glaukos Company Profile

(Get Free Report)

Glaukos Corporation is an ophthalmic medical-technology company focused on developing and commercializing therapies for chronic eye diseases. The company’s principal areas of focus include glaucoma, corneal disorders and retinal diseases, with an emphasis on treatments that may reduce reliance on conventional pharmaceuticals or more invasive surgical procedures.

Glaukos is best known for its micro-invasive glaucoma surgery (MIGS) products, including the iStent family of implantable devices used to help lower intraocular pressure in patients with glaucoma.